Myriad Genetics

About:

Myriad Genetics discovers, develops, and commercializing novel therapies for the treatment of cancer.

Website: http://www.myriad.com

Twitter/X: myriadgenetics

Description:

Myriad Genetics personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.

Total Funding Amount:

$90M

Estimated Revenue Range:

$500M to $1B

Headquarters Location:

Salt Lake City, Utah, United States

Founded Date:

1991-01-01

Contact Email:

cscomments(AT)myriad.com

Founders:

Kevin Kimberlin, Mark Skolnick, Peter D. Meldrum, Walter Gilbert

Number of Employees:

1001-5000

Last Funding Date:

2023-07-06

IPO Status:

Public

Industries:

© 2025 bioDAO.ai